Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis.

被引：0
|
作者：
Gazzoni, Gabriela
Vilbert, Maysa
Oliveira, Joao Pedro
Dacoregio, Maria Inez
Michelon, Isabella
Reis, Pedro
Braga, Marcelo
Simoes, Clara
Oliveira, Lilia
Cardoso, Ana Paula Garcia
机构：
[1] Hosp Servidor Publ Estadual, Sao Paulo, Brazil
[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[3] Univ Fed Rio de Janeiro, Rio de Janeiro, Brazil
[4] Univ Estadual Ctr Oeste UNICTR, Guarapuava, Brazil
[5] Univ Catolica Pelotas, Pelotas, RS, Brazil
[6] Univ Fed Rio de Janeiro, Rio de Janeiro, Brazil
[7] Fac Multivix, Vitoria, Brazil
[8] Harvard TH Chan Sch Publ Hlth, Boston, MA USA
[9] Hosp Israelita Albert Einstein, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.761
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Biomarkers of treatment (Tx)-related toxicity in advanced urothelial carcinoma (aUC) pts treated with enfortumab vedotin (EV): Analysis of UNITE study
    Nizam, A.
    Zhang, L.
    Jindal, T.
    Nguyen, C. B.
    Alhalabi, O.
    Basu, A.
    Evans, S. P.
    Hoimes, C. J.
    Zakharia, Y.
    Milowsky, M. I.
    Kilari, D.
    Shah, S. A.
    Davis, N. B.
    Emamekhoo, H.
    Gupta, S.
    Bellmunt, J.
    Grivas, P.
    Campbell, M. T.
    Alva, A.
    Koshkin, V. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1219 - S1219
  • [42] Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis
    Taguchi, Satoru
    Kawai, Taketo
    Ambe, Yoshiki
    Kishitani, Kenjiro
    Noda, Michio
    Kaneko, Tomoyuki
    Miyakawa, Jimpei
    Nakamura, Yu
    Hoshina, Hayato
    Obinata, Daisuke
    Yamaguchi, Kenya
    Kakutani, Shigenori
    Furuya, Yoshitsune
    Sato, Yujiro
    Adachi, Yume
    Sugimoto, Kazuma
    Sato, Keigo
    Tabata, Mariko
    Tanaka, Takehiro
    Nara, Katsuhiko
    Uemura, Yukari
    Kamei, Jun
    Akiyama, Yoshiyuki
    Sato, Yusuke
    Yamada, Yuta
    Niimi, Aya
    Yamada, Daisuke
    Takada, Tappei
    Takahashi, Sayuri
    Yamada, Yukio
    Miyazaki, Hideyo
    Enomoto, Yutaka
    Nishimatsu, Hiroaki
    Fujimura, Tetsuya
    Fukuhara, Hiroshi
    Nakagawa, Tohru
    Takahashi, Satoru
    Kume, Haruki
    INTERNATIONAL JOURNAL OF UROLOGY, 2025, 32 (03) : 270 - 276
  • [43] Safety Analysis of Co-Administration of Radiation Therapy with Enfortumab Vedotin Based Regimens in Metastatic Urothelial Carcinoma
    Seyedin, S. N.
    Harada, G. K.
    Garemanian, E.
    Rafizadeh, D.
    Kaakour, D.
    Dwabe, S.
    Rezazadeh, A.
    Daneshvar, M.
    Mar, N.
    CLINICAL GENITOURINARY CANCER, 2024, 22 (06)
  • [44] Clinical outcomes of immunotherapy in metastatic pancreatic carcinoma: A systematic review and meta-analysis.
    Shahzad, Moazzam
    Vyas, Abhinav
    Dave, Prashil
    Irfan, Sohaib
    Khan, Abat
    Chaudhry, Ahtshamullah
    Qasim, Hana
    Khizer, Umair
    Khalid, Muhammad Fareed
    Shabbir, Muhammad
    Jaglal, Michael Vishal
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 688 - 688
  • [45] Valerian for sleep: A systematic review and meta-analysis.
    Bent, S
    Padula, A
    Moore, DH
    Patterson, M
    Mehling, W
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2005, 20 : 90 - 90
  • [46] Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis
    Shuai, Hui
    Duan, Xi
    Zhou, Jun-Jie
    Liu, Yuan
    Wu, Tao
    BMC UROLOGY, 2023, 23 (01)
  • [47] Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis
    Hui Shuai
    Xi Duan
    Jun-Jie Zhou
    Yuan Liu
    Tao Wu
    BMC Urology, 23
  • [48] EVALUATION OF QTC INTERVAL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA FOLLOWING ENFORTUMAB VEDOTIN ADMINISTRATION.
    Yamada, A.
    Fukushi, R.
    Kadokura, T.
    Garg, A.
    Tang, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S58 - S58
  • [49] Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China
    Li, Siming
    Shi, Yanxia
    Dong, Haiying
    Guo, Hongqian
    Xie, Yu
    Sun, Zhongquan
    Zhang, Xiaoping
    Kim, Eric
    Zhang, Jun
    Li, Yue
    Xu, Chenming
    Kadeerbai, Haishan
    Lee, Sue
    Gorla, Seema
    Guo, Jun
    Sheng, Xinan
    CANCER MEDICINE, 2024, 13 (21):
  • [50] Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV)
    Jiang, Cindy
    Alhalabi, Omar
    Haro-Silerio, Jaime
    Qiao, Wei
    Shah, Amishi Yogesh
    Siefker-Radtke, Arlene O.
    Gao, Jianjun
    Goswami, Sangeeta
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    Guo, Charles
    Campbell, Matthew T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345